Kala Bio, INC. (KALA) — 10-Q Filings

10-Q Filings (6)

• KALA BIO Halts Key Drug Development, Cuts Staff Amid Cash Crunch — Nov 19, 2025 Risk: high
  KALA BIO, Inc. reported a net loss of $27.666 million for the nine months ended September 30, 2025, a slight improvement from the $30.336 million loss in the sa
• KALA BIO Narrows Q2 Loss Amidst Continued Equity Raises — Aug 8, 2025 Risk: high
  KALA BIO, Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with the prior year periods. The company's net loss for the thre
• Kala Bio Q1 Loss Narrows, Cash Reserves Stand at $51.25M — May 14, 2025 Risk: medium
  Kala Bio, Inc. reported its first quarter 2025 results for the period ending March 31, 2025. The company's financial statements show a net loss of $6.41 million
• Kala Bio Q3 2024: $275.9M Assets, $4.6M Cash — Nov 12, 2024 Risk: medium
  Kala Bio, Inc. reported its third quarter 2024 results, with total assets reaching $275.9 million as of September 30, 2024. The company's cash and cash equivale
• Kala Bio Q2 2024: Assets $276M, Liabilities $4.6M — Aug 6, 2024 Risk: medium
  Kala Bio, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported total assets of $275,937,200 and total liabilities of $4,598,419. Signif
• Kala Bio, Inc. Files 10-Q for Period Ending March 31, 2024 — May 14, 2024 Risk:
  KALA BIO, Inc. (KALA) filed a Quarterly Report (10-Q) with the SEC on May 14, 2024. Kala Bio, Inc. reported $0 in revenue for the quarter ended March 31, 2024.

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX